

PATENT  
CUSTOMER NO: 32425

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Donald W. KUFE  
Surender KHARBANDA

Serial No.: 10/598,295

Filed: August 23, 2006

For: MUC1 ANTAGONIST ENHANCEMENT  
OF DEATH RECEPTOR LIGAND-  
INDUCED APOPTOSIS

Group Art Unit: 1635

Examiner: Unknown

Atty. Dkt. No.: DFCI:006US

Confirmation No.: 2459

ELECTION UNDER 37 C.F.R. §§ 3.71 AND 3.73  
AND POWER OF ATTORNEY

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

The undersigned, being an Assignee of record of an interest in the above-identified application by virtue of an assignment recorded in the United States Patent and Trademark Office as set forth below, hereby elects, under 37 C.F.R. § 3.71, to prosecute the application to the exclusion of the inventors.

The Assignee hereby revokes any previous Powers of Attorney and appoints all attorneys or agents associated with Customer Number 32425, each of whom is an attorney or agent with the firm of FULBRIGHT & JAWORSKI L.L.P., as its attorney or agent, for so long as they remain with such firm, with full power of substitution and revocation, to prosecute the application, to make alterations and amendments therein, to transact all business in the Patent and Trademark Office in connection therewith, and to receive any Letters Patent.

Pursuant to 37 C.F.R. § 3.73, the undersigned has reviewed the evidentiary documents, specifically the Assignment to Genzyme Corporation, referenced below, and certifies that to the best of my knowledge and belief, title remains in the name of the Assignee.

Please direct all communications as follows:

Monica A. De La Paz  
FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

ASSIGNEE:  
Genzyme Corporation

By: Bart G Newland  
Name: Bart G Newland  
Title: Vice President  
Date: 7/0/07

ASSIGNMENT:

- Concurrently filed  
 Previously recorded

Date: February 6, 2007

Reel: 018858

Frames: 0698